| Literature DB >> 35874912 |
Ming-Chuan Lee1, Yu-Tsang Wang2, Yu-Ju Li1, Ching-Yi Tsai1, Su-Te Chen1, Wun-Jyun Jhuang1,3, Meng-Chi Chang1, Mei-Yu Chien1, Hsiang-Chun Lee1,3,4,5.
Abstract
Purpose: Manifestations of metabolic syndrome (MetS) carry risks for atrial fibrillation (AF). The study determined whether any electrocardiographic parameter can reflect increased AF risk in individuals with MetS. Patients andEntities:
Keywords: QTc interval; atrial fibrillation; electrocardiography; lipid; metabolic syndrome
Year: 2022 PMID: 35874912 PMCID: PMC9296885 DOI: 10.2147/IJGM.S361705
Source DB: PubMed Journal: Int J Gen Med ISSN: 1178-7074
Figure 1Flow diagram for patient inclusion in the analysis.
Comparisons Between Individuals with and without AF
| Variables | AF Absent n = 3925 | AF Present n = 554 | P-value |
|---|---|---|---|
| Age (years) | 67 ± 13.5 | 73.9 ± 11.8 | <0.001 |
| Male, n (%) | 2300 (58.6) | 316 (57) | 0.485 |
| DM, n (%) | 2580 (65.7) | 333 (60.1) | 0.009 |
| Hypertension, n (%) | 3206 (81.7) | 474 (85.6) | 0.025 |
| Gout, n (%) | 300 (7.6) | 51 (9.2) | 0.200 |
| Hyperlipidemia, n (%) | 2340 (57.6) | 272 (49.1) | <0.001 |
| Biochemistry | |||
| ALT, IU/L | 30.1 ± 43.3 | 26.4 ± 19.9 | 0.003 |
| Creatinine, mg/dL | 1.8 ± 2.1 | 1.5 ± 1.3 | <0.001 |
| eGFR, mL/min | 68.8 ± 41.4 | 64.1 ± 30.9 | 0.004 |
| Glucose, mg/dL | 126.2 ± 51.8 | 121.3 ± 41.8 | 0.024 |
| Total cholesterol, mg/dL | 172.2 ± 48.3 | 155.8 ± 42.5 | <0.001 |
| HDL-C, mg/dL | 40.1 ± 13.2 | 41.4 ± 13.7 | 0.037 |
| LDL-C, mg/dL | 103.4 ± 39.4 | 91.6 ± 35.0 | <0.001 |
| VLDL-C, mg/dL | 28.8 ± 18.2 | 22.8 ± 13.3 | <0.001 |
| non-HDL-C, mg/dL | 132.1 ± 46.0 | 114.5 ± 40.5 | <0.001 |
| Triglyceride, mg/dL | 138 ± 97.3 | 107 ± 65.8 | <0.001 |
| Medications | |||
| ß-blockers, n (%) | 300 (7.6) | 52 (9.4) | 0.153 |
| Lipid-lowering, n (%) | 92 (2.3) | 15 (2.7) | 0.599 |
| Antiarrhythmics, n (%) | 13 (0.3) | 19 (3.4) | <0.001 |
| Anti-coagulants, n (%) | 129 (3.3) | 20 (3.6) | 0.691 |
| Electrocardiographic parameters | |||
| QRS, ms | 94.5 ± 24.1 | 95.7 ± 23.7 | 0.262 |
| QTc, ms | 426.1 ± 35.4 | 427.9 ± 48.1 | 0.392 |
| QQRS, ms | |||
| Q1 (< 82), n (%) | 1081 (27.5) | 154 (27.8) | 0.524 |
| Q2 (82–90), n (%) | 1019 (26.0) | 137 (24.7) | |
| Q3 (90–100), n (%) | 879 (22.4) | 115 (20.8) | |
| Q4 (> 100), n (%) | 946 (24.1) | 148 (26.7) | |
| QQTc, ms | |||
| Q1 (< 404), n (%) | 972 (24.8) | 158 (28.5)* | 0.008 |
| Q2 (404–424), n (%) | 1033 (26.3) | 115 (20.8) | |
| Q3 (424–444), n (%) | 981 (25.0) | 129 (23.3) | |
| Q4 (> 444), n (%) | 939 (23.9) | 152 (27.4)* | |
Notes: Values are given as mean ± SD or number, or percentage in the specific group. Chi-square is used for category variable. *Indicates P value< 0.05.
Abbreviations: DM, diabetes mellitus; ALT, alanine aminotransferase; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; VLDL-C, very-low-density lipoprotein cholesterol; P, P wave duration; PR, PR interval; QRS, QRS width; QTc, corrected QT interval; QQRS, quartiles of the QRS width; QQTc, quartiles of the QTc interval.
Correlations of Clinical Characteristics and Other Electrocardiographic Parameters in the Quartiles of QTc
| Variables | QQTc1 (< 404 ms) n = 972 | QQTc2 (404–424 ms) n = 1033 | QQTc3 (424–444 ms) n = 981 | QQTc4 (>444 ms) n = 939 | P-value |
|---|---|---|---|---|---|
| Age | 66.3 ± 13.6 | 66.3 ± 13.1 | 67.1 ± 13.3 | 68.4 ± 13.9 | 0.001 |
| Male, n (%) | 604 (62.1) | 631 (61.1) | 571 (58.2) | 494 (52.6) | <0.001 |
| VLDL-C, mg/dL | 27.4 ± 15.9 | 29.6 ± 18.8 | 28.7 ± 19 | 29.3 ± 19.1 | 0.034 |
| Triglyceride, mg/dL | 132.3 ± 86.8 | 143.8 ± 106.8 | 138.6 ± 100.4 | 136.9 ± 93.1 | 0.068 |
| Cholesterol, mg/dL | 170.4 ± 48.9 | 174.7 ± 46.9 | 173.5 ± 48.8 | 170 ± 48.6 | 0.081 |
| HDL-C, mg/dL | 40 ± 13.2 | 40.1 ± 13 | 40.5 ± 12.8 | 39.7 ± 13.9 | 0.634 |
| LDL-C, mg/dL | 103.1 ± 41 | 105 ± 38.2 | 104.3 ± 38.6 | 101 ± 39.8 | 0.132 |
| ALT, IU/L | 32 ± 37.6 | 28.8 ± 20.3 | 30 ± 57.9 | 29.7 ± 49.4 | 0.510 |
| Creatinine, mg/dL | 1.4 ± 1.5 | 1.5 ± 1.7 | 1.9 ± 2.2 | 2.3 ± 2.8 | <0.001 |
| eGFR, mL/min | 77.8 ± 46.5 | 71.9 ± 36.5 | 64.9 ± 40.3 | 59.9 ± 39.5 | <0.001 |
| Glucose, mg/dL | 124 ± 45.4 | 125.8 ± 53.5 | 125.7 ± 50.2 | 129.4 ± 57.6 | 0.213 |
| DM, n (%) | 630 (64.8) | 670 (64.9) | 634 (64.6) | 646 (68.8) | 0.160 |
| Hypertension, n (%) | 777 (79.9) | 829 (80.3) | 822 (83.8) | 778 (82.9) | 0.066 |
| Hyperlipidemia, n (%) | 595 (61.2) | 626 (60.6) | 594 (60.6) | 526 (55.9) | 0.067 |
| B-blocker, n (%) | 76 (7.8) | 68 (6.6) | 70 (7.1) | 86 (9.2) | 0.164 |
| Lipid-lowering, n (%) | 19 (2) | 24 (2.3) | 23 (2.3) | 26 (2.8) | 0.708 |
| Anti-arrhythmias, n (%) | 4 (0.4) | ≦2 (0) | 4 (0.4) | 3 (0.3) | 0.810 |
| Anti-coagulants, n (%) | 18 (1.9) | 47 (4.5) | 32 (3.3) | 32 (3.4) | 0.009 |
| Gout, n (%) | 55 (5.7) | 88 (8.5) | 73 (7.4) | 84 (9) | 0.031 |
| Sleep apnea, n (%) | ≦2 (0) | ≦2 (0) | ≦2 (0) | ≦2 (0) | 0.799 |
| PR (msec) | 167.6 ± 29.9 | 170.3 ± 30.7 | 173.9 ± 33.6 | 175.6 ± 36.5 | <0.001 |
| QRS (msec) | 87 ± 11.8 | 90.5 ± 19.4 | 95.3 ± 30.2 | 105.7 ± 26.8 | <0.001 |
| P (msec) | 109 ± 17.8 | 109.8 ± 17.3 | 110.7 ± 17.5 | 110.2 ± 19.2 | 0.191 |
| Non-HDL (msec) | 130.4 ± 46.4 | 134.6 ± 44.1 | 133 ± 46.8 | 130.3 ± 46.9 | 0.108 |
Univariate and Multivariate Analysis for the Presence of AF
| Variables | Univariate | Multivariate | |||||
|---|---|---|---|---|---|---|---|
| Odds Ratio | 95% CI | P-value | Odds Ratio | 95% CI | P-value | ||
| Age | 1.04 | 1.04–1.05 | <0.001 | 1.036 | 1.025–1.046 | <0.001 | |
| Male | 0.94 | 0.78–1.12 | 0.485 | 1.177 | 0.936–1.481 | 0.163 | |
| VLDL-C | 0.97 | 0.96–0.98 | <0.001 | ||||
| Triglyceride | 0.99 | 0.99–1 | <0.001 | 0.999 | 0.996–1.002 | 0.588 | |
| Cholesterol | 0.99 | 0.99–0.99 | <0.001 | 0.986 | 0.972–1.000 | 0.050 | |
| HDL-C | 1.01 | 1–1.01 | 0.037 | 1.015 | 0.998–1.032 | 0.080 | |
| LDL-C | 0.99 | 0.99–0.99 | <0.001 | 1.008 | 0.994–1.024 | 0.266 | |
| ALT | 1 | 0.99–1 | 0.049 | 0.998 | 0.994–1.003 | 0.499 | |
| eGFR | 1 | 0.99–1 | 0.019 | 1 | 0.997–1.003 | 0.987 | |
| AC glucose | 1 | 1–1 | 0.056 | ||||
| DM | 0.79 | 0.66–0.94 | 0.009 | 0.84 | 0.672–1.061 | 0.147 | |
| Hypertension | 1.33 | 1.03–1.71 | 0.026 | 1.1 | 0.8–1.52 | 0.561 | |
| Hyperlipidemia | 0.65 | 0.55–0.78 | <0.001 | 0.886 | 0.706–1.112 | 0.295 | |
| B-blocker | 1.25 | 0.92–1.71 | 0.154 | ||||
| Lipid-lowering | 1.16 | 0.67–2.02 | 0.600 | ||||
| Anti-arrhythmias | 10.68 | 5.24–21.75 | <0.001 | 12.129 | 5.004–29.398 | <0.001 | |
| Anti-coagulants | 1.10 | 0.68–1.78 | 0.691 | 0.545 | 0.273–1.089 | 0.086 | |
| Gout | 1.23 | 0.9–1.67 | 0.201 | ||||
| QRS (ms) | 1 | 1–1.01 | 0.264 | ||||
| QTc (ms) | 1 | 1–1 | 0.283 | ||||
| non-HDL | 0.99 | 0.99–0.99 | <0.001 | ||||
| QQRS (ms) | |||||||
| Q1 | 1.06 | 0.83–1.36 | 0.644 | ||||
| Q2 (Ref) | - | - | - | ||||
| Q3 | 0.97 | 0.75–1.49 | 0.839 | ||||
| Q4 | 1.16 | 0.91–0 | 0.232 | ||||
| QQTc (ms) | |||||||
| Q1 | 1.46 | 1.13–1.89 | 0.003 | 1.147 | 0.843–1.559 | 0.382 | |
| Q2 (Ref) | Ref | - | - | Ref | - | - | |
| Q3 | 1.18 | 0.91–1.54 | 0.220 | 1.134 | 0.832–1.547 | 0.426 | |
| Q4 | 1.45 | 1.12–1.88 | 0.004 | 1.099 | 0.804–1.502 | 0.552 | |
Abbreviations: DM, diabetes mellitus; ALT, alanine aminotransferase; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; VLDL-C, very-low-density lipoprotein cholesterol; P, P wave duration; PR, PR interval; QRS, QRS width; QTc, corrected QT interval; QQRS, quartiles of the QRS width; QQTc, quartiles of the QTc interval; Ref, reference.